Specialised Therapeutics, an independent biopharmaceutical business, has become a member of the World Orphan Drug Alliance (WODA), a global alliance of pharmaceutical firms created to increase patient access to novel therapies for rare illnesses.

WODA works by discovering biotechnology and pharmaceutical businesses and giving them the chance to market their revolutionary medicines for rare illnesses in participating nations. Currently, these kinds of treatment are often not accessible to individuals across many regions.

“Specialised Therapeutics, an independent biopharmaceutical business, has become a member of the World Orphan Drug Alliance “

Head of WODA, Patrick Jordan, said that “WODA’s commercial presence has now extended to an impressive number of 152 markets covered by nine like-minded pharmaceutical companies, providing extensive global outreach with a local focus. Our members are experienced and high-performance commercialisation companies, each being an expert in their own region.”

“Through seamless collaboration, we provide our partners with a single platform for full commercialisation of medicines, tailored to both partner and product needs.”

Chief Executive Officer of Specialised Therapeutics, Carlo Montagner, highlighted that ST's vision closely complements WODA's objective to use new treatments to meet the medical gaps of local populations.

“We firmly believe that patients in our regions should have access to the same innovative treatments as patients have in larger markets like the US and Europe.”

“I am confident that our WODA membership will further expand our capabilities, enabling us to provide additional therapies where there is an unmet need.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.